{"nctId":"NCT00134030","briefTitle":"Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma","startDateStruct":{"date":"2005-11-14","type":"ACTUAL"},"conditions":["Localized Osteosarcoma","Metastatic Osteosarcoma"],"count":1334,"armGroups":[{"label":"Maintenance therapy group 1 arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cisplatin","Drug: Doxorubicin Hydrochloride","Drug: Methotrexate","Other: Quality-of-Life Assessment","Other: Questionnaire Administration","Procedure: Therapeutic Conventional Surgery"]},{"label":"Maintenance therapy group 1 arm II","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Drug: Doxorubicin Hydrochloride","Drug: Methotrexate","Biological: Peginterferon Alfa-2b","Other: Quality-of-Life Assessment","Other: Questionnaire Administration","Procedure: Therapeutic Conventional Surgery"]},{"label":"Maintenance therapy group 2 arm I","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cisplatin","Drug: Doxorubicin Hydrochloride","Drug: Methotrexate","Other: Quality-of-Life Assessment","Other: Questionnaire Administration","Procedure: Therapeutic Conventional Surgery"]},{"label":"Maintenance therapy group 2 arm II","type":"EXPERIMENTAL","interventionNames":["Drug: Cisplatin","Drug: Doxorubicin Hydrochloride","Drug: Etoposide","Drug: Ifosfamide","Drug: Methotrexate","Other: Quality-of-Life Assessment","Other: Questionnaire Administration","Procedure: Therapeutic Conventional Surgery"]}],"interventions":[{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone''s Chloride","Peyrone''s Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"Doxorubicin Hydrochloride","otherNames":["5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)","ADM","Adriacin","Adriamycin","Adriamycin Hydrochloride","Adriamycin PFS","Adriamycin RDF","ADRIAMYCIN, HYDROCHLORIDE","Adriamycine","Adriblastina","Adriblastine","Adrimedac","Chloridrato de Doxorrubicina","DOX","DOXO-CELL","Doxolem","Doxorubicin HCl","Doxorubicin.HCl","Doxorubin","Farmiblastina","FI 106","FI-106","hydroxydaunorubicin","Rubex"]},{"name":"Etoposide","otherNames":["Demethyl Epipodophyllotoxin Ethylidine Glucoside","EPEG","Lastet","Toposar","Vepesid","VP 16","VP 16-213","VP-16","VP-16-213","VP16"]},{"name":"Ifosfamide","otherNames":["Asta Z 4942","Asta Z-4942","Cyfos","Holoxan","Holoxane","Ifex","IFO","IFO-Cell","Ifolem","Ifomida","Ifomide","Ifosfamidum","Ifoxan","IFX","Iphosphamid","Iphosphamide","Iso-Endoxan","Isoendoxan","Isophosphamide","Mitoxana","MJF 9325","MJF-9325","Naxamide","Seromida","Tronoxal","Z 4942","Z-4942"]},{"name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"name":"Peginterferon Alfa-2b","otherNames":["PEG Interferon Alpha-2b","PEG Intron","PEG-IFN Alfa-2b","PEG-IFN-a 2b","PEG-Interferon Alfa-2b","PEG-Intron","Pegylated Interferon Alpha-2b","Polyethylene Glycol IFN-A2b","Polyethylene Glycol Interferon Alfa-2b","SCH 54031","Sylatron"]},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"]},{"name":"Questionnaire Administration","otherNames":[]},{"name":"Therapeutic Conventional Surgery","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed high-grade osteosarcoma, including second malignancies\n\n  * Localized or metastatic disease\n  * The primary tumor must be located in the limbs or axial skeleton, including any of the following sites\\*:\n\n    * Long bone of upper limb\n    * Short bone of upper limb\n    * Long bone of lower limb\n    * Short bone of lower limb\n    * Vertebral column\n    * Ribs, sternum, clavicle, or scapula\n    * Pelvic bones, sacrum, or coccyx\n* Tumor (primary, metastatic, or both) resectable OR is expected to become resectable after neoadjuvant induction chemotherapy\n* Suitable for neoadjuvant chemotherapy\n* Performance status - Lansky 50-100% (for patients under 16 years of age)\n* Performance status - Karnofsky 50-100%\\*\n* Performance status - WHO or ECOG 0-2\\*\n* Platelet count ≥ 100,000/mm³\n* Neutrophil count ≥ 1,500/mm³\n* WBC ≥ 3,000/mm³\n* Bilirubin ≤ 1.5 times upper limit of normal\n* Creatinine clearance ≥ 70 mL/min\n* Creatinine based on age as follows:\n\n  * No greater than 1.0 mg/dL (for patients 5 to 10 years of age)\n  * No greater than 1.2 mg/dL (for patients 11 to 15 years of age)\n  * No greater than 1.5 mg/dL (for patients over 15 years of age)\n* Ejection fraction ≥ 50% by radionuclide angiogram\n* Shortening fraction ≥ 28% by echocardiogram\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No known HIV positivity\n* No prior chemotherapy for any disease\n* Prior radiotherapy for another malignancy allowed\n* No prior treatment for osteosarcoma\n* No patients with any of the following:\n\n  * Craniofacial osteosarcoma","healthyVolunteers":false,"sex":"ALL","minimumAge":"5 Years","maximumAge":"40 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival (EFS)","description":"EFS is defined as time from randomisation to the first of: death, detection of local recurrence or metastasis, progression of metastatic disease, or detection of a secondary malignancy.\n\nEFS will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Follow up per participant will be assessed for up to 10 years. The 3 year EFS is provided as a summary.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"55","spread":null},{"groupId":"OG003","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Overall Survival","description":"Overall survival is time from randomization until death from any cause.\n\nWill be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Participants will be assessed for up to 10 years. 5 year overall survival is provided as a summary.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"68","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0","description":"Percentages of patients experiencing grade 3 and 4 adverse events. These will be compared using chi-square tests or Fisher's exact tests where appropriate.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348","spread":null},{"groupId":"OG001","value":"340","spread":null},{"groupId":"OG002","value":"287","spread":null},{"groupId":"OG003","value":"281","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":49,"n":359},"commonTop":[]}}}